Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring (Jan 2018)

Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project

  • Eline A.J. Willemse,
  • Ingrid S. vanMaurik,
  • Betty M. Tijms,
  • Femke H. Bouwman,
  • Andreas Franke,
  • Isabelle Hubeek,
  • Leo Boelaarts,
  • Jules J. Claus,
  • Esther S.C. Korf,
  • Rob J. vanMarum,
  • Gerwin Roks,
  • Niki Schoonenboom,
  • Nicolaas Verwey,
  • Marissa D. Zwan,
  • Simone Wahl,
  • Wiesje M. van derFlier,
  • Charlotte E. Teunissen

DOI
https://doi.org/10.1016/j.dadm.2018.08.006
Journal volume & issue
Vol. 10, no. 1
pp. 563 – 572

Abstract

Read online

Abstract Introduction We compared the automated Elecsys and manual Innotest immunoassays for cerebrospinal fluid (CSF) Alzheimer's disease biomarkers in a multicenter diagnostic setting. Methods We collected CSF samples from 137 participants in eight local memory clinics. Amyloid β(1–42) (Aβ42), total tau (t‐tau), and phosphorylated tau (p‐tau) were centrally analyzed with Innotest and Elecsys assays. Concordances between methods were assessed. Results Biomarker results strongly correlated between assays with Spearman's ρ 0.94 for Aβ42, 0.98 for t‐tau, and 0.98 for p‐tau. Using Gaussian mixture modeling, cohort‐specific cut‐points were estimated at 1092 pg/mL for Aβ42, 235 pg/mL for t‐tau, and 24 pg/mL for p‐tau. We found an excellent concordance of biomarker abnormality between assays of 97% for Aβ42 and 96% for both t‐tau and p‐tau. Discussion The high concordances between Elecsys and Innotest in this nonacademic, multicenter cohort support the use of Elecsys for CSF Alzheimer's disease diagnostics and allow conversion of results between methods.

Keywords